These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 20632248)

  • 1. Recombinant factor IX for clinical and research use.
    Monahan PE; Di Paola J
    Semin Thromb Hemost; 2010 Jul; 36(5):498-509. PubMed ID: 20632248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemophilia B: current pharmacotherapy and future directions.
    Franchini M; Frattini F; Crestani S; Bonfanti C
    Expert Opin Pharmacother; 2012 Oct; 13(14):2053-63. PubMed ID: 22946758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current management of hemophilia B: recommendations, complications and emerging issues.
    Franchini M
    Expert Rev Hematol; 2014 Oct; 7(5):573-81. PubMed ID: 25112898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant factor IX.
    White GC; Beebe A; Nielsen B
    Thromb Haemost; 1997 Jul; 78(1):261-5. PubMed ID: 9198163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing the treatment of haemophilia B: laboratory and clinical perspectives.
    Aledort LM
    Haemophilia; 2010 Jul; 16 Suppl 6():1-2. PubMed ID: 20561350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.
    Windyga J; Abbuehl BE; Hafeman AE
    Expert Rev Hematol; 2014 Jun; 7(3):333-42. PubMed ID: 24832133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
    Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
    Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant FIXFc: a novel therapy for the royal disease?
    Valentino LA
    Expert Opin Biol Ther; 2011 Oct; 11(10):1361-8. PubMed ID: 21780945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hemophilia B replacement therapy drugs].
    Yan H; Zeng F
    Sheng Wu Gong Cheng Xue Bao; 2016 Feb; 32(2):164-71. PubMed ID: 27382766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical studies of recombinant factor IX.
    Schaub R; Garzone P; Bouchard P; Rup B; Keith J; Brinkhous K; Larsen G
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):28-32. PubMed ID: 9565164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant factor IX for the treatment of hemophilia B. Introduction.
    Thompson A
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):1-3. PubMed ID: 9565159
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of recombinant factor IX and thromboelastography in a patient with hemophilia B undergoing liver transplantation: a case report.
    De Pietri L; Masetti M; Montalti R; Begliomini B; Reggiani A; Barbieri E; Biagioni E; Marietta M; Romano A; Pasetto A; Gerunda GE
    Transplant Proc; 2008; 40(6):2077-9. PubMed ID: 18675136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The manufacturing process for recombinant factor IX.
    Harrison S; Adamson S; Bonam D; Brodeur S; Charlebois T; Clancy B; Costigan R; Drapeau D; Hamilton M; Hanley K; Kelley B; Knight A; Leonard M; McCarthy M; Oakes P; Sterl K; Switzer M; Walsh R; Foster W
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):4-10. PubMed ID: 9565160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of recombinant factor IX.
    White G; Shapiro A; Ragni M; Garzone P; Goodfellow J; Tubridy K; Courter S
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):33-8. PubMed ID: 9565165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging drugs for hemophilia B.
    Mannucci PM; Franchini M
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):407-14. PubMed ID: 25098797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
    Aznar JA; Cabrera N; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañés M; Páez AM; Lissitchkov T
    Haemophilia; 2009 Nov; 15(6):1243-8. PubMed ID: 19659601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of Rixubis™ in the treatment of hemophilia B.
    Valentino LA
    Immunotherapy; 2014; 6(4):381-94. PubMed ID: 24815779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galectin 3-binding protein is a potential contaminant of recombinantly produced factor IX.
    Blostein M; Cuerquis J; Galipeau J
    Haemophilia; 2007 Nov; 13(6):701-6. PubMed ID: 17973845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Half-life extension through albumin fusion technologies.
    Schulte S
    Thromb Res; 2009 Dec; 124 Suppl 2():S6-8. PubMed ID: 20109653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvements in factor concentrates.
    Lillicrap D
    Curr Opin Hematol; 2010 Sep; 17(5):393-7. PubMed ID: 20613509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.